Skip to main content

Table 4 Incidence and categories of hyperglycemia in accordance to scheme of GC therapy

From: Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients

Variable

CGC n = 12

CyGC n = 20

P*

PAD (mg/patient)

   

8 weeks

4200

1500

-

12 weeks

-

2500

-

Fasting hyperglycemia (≥5.60 mmol/L)

   

Incidence, n (%)

12 (100)

10 (50)

0.003*

Plasma glucose (mmol/L)

8.22 ± 3.79

6.50 ± 0.64

0.16

Prediabetes (≥5.60- < 7.00 mmol/L)

   

Incidence, n (%)

5 (41.6)

6 (30)

0.51

DM (fasting glycemia ≥7.00 mmol/L)

   

Incidence, n (%)

7 (58.3)

4 (20)

0.22

Plasma glucose (mmol/L)

9.83 ± 4.39

7.11 ± 0.15

0.26

DM occurrence - week, n (%)

   

First

0 (0)

0 (0)

-

Second to fourth

5 (71.4)

0 (0)

-

Fifth to eighth

2 (28.5)

4 (100)

-

Postprandial hyperglycemia

   

Incidence, n (%)

1 (8.3)

4 (20)

0.62

  1. All data are reported in total number of subjects and (%) or mean ± SD.
  2. CGC, continuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen; PAD, prednisone accumulative dose; DM, diabetes mellitus.
  3. *Significant P value ≤0.05.